entertainment -WSS

entertainment

author：comprehensive 2025-09-28 01:37:06 - browse：93952

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Decaf coffee targeted by food safety group under obscure FDA rule

WSS

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Study says nonprofit hospitals fall short in charity care spending

Primary care physicians play key roles in Alzheimer's management

Reframing the conversation around gain

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

Readout LOUD podcast: mifepristone case, GLP

hotspot

entertainment

explore

What does generative AI mean for health care? We asked experts

Florida babysitter arrested over hot car death, authorities say

As demand for Covid shots wanes, Moderna seeks its next success

The biotech scorecard for the 2nd quarter: 12 industry events to watch

New air purifier tech could be key to improving indoor air quality

'The View' co

Guidelines to prevent youth baseball injuries need more muscle

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Sports medicine is finally prioritizing gender equality

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

focus

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Why the advice to take all your antibiotics may be wrong

Biden White House, tech companies launch new safeguards around emerging AI technology

Donor acceptance rates hint at racial, gender bias in heart transplants: study

EMA weighs against approval for Mirati's lung cancer drug

New chief aims to remake Sanofi Genzyme

leisure time

Wikipedia

focus

entertainment